{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:02:27Z","timestamp":1780617747827,"version":"3.54.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:00:00Z","timestamp":1503446400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the CAMS Innovation Fund for Medical Sciences","award":["2016-12M-1-002"],"award-info":[{"award-number":["2016-12M-1-002"]}]},{"name":"The National Key Research and Development Program of China","award":["2016YFC0901503"],"award-info":[{"award-number":["2016YFC0901503"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00277-017-3114-7","type":"journal-article","created":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T19:42:22Z","timestamp":1503430942000},"page":"185-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy of intermediate-dose cytarabine in central nervous system-relapsed wild-type BRAF Erdheim-Chester disease"],"prefix":"10.1007","volume":"97","author":[{"given":"Xin-xin","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao-bin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4549-0694","authenticated-orcid":false,"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,23]]},"reference":[{"key":"3114_CR1","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","volume":"116","author":"G Badalian-Very","year":"2010","unstructured":"Badalian-Very G, Vergilio JA, Degar BA et al (2010) Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116:1919\u20131923","journal-title":"Blood"},{"key":"3114_CR2","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/blood-2012-05-430140","volume":"120","author":"J Haroche","year":"2012","unstructured":"Haroche J, Charlotte F, Arnaud L et al (2012) High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 120:2700\u20132703","journal-title":"Blood"},{"key":"3114_CR3","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00277-016-2606-1","volume":"95","author":"XX Cao","year":"2016","unstructured":"Cao XX, Sun J, Li J et al (2016) Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults. Ann Hematol 95:745\u2013750","journal-title":"Ann Hematol"},{"key":"3114_CR4","doi-asserted-by":"publisher","unstructured":"Milne P, Bigley V, Bacon CM et al (2017) Hematopoietic origin of Langerhans cell histiocytosis and Erdheim Chester disease in adults. Blood. https:\/\/doi.org\/10.1182\/blood-2016-12-757823","DOI":"10.1182\/blood-2016-12-757823"},{"key":"3114_CR5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/asheducation-2015.1.571","volume":"2015","author":"J Haroche","year":"2015","unstructured":"Haroche J, Abla O (2015) Uncommon histiocytic disorders: Rosai\u2013Dorfman, juvenile xanthogranuloma, and Erdheim\u2013Chester disease. Hematology Am Soc Hematol Educ Program 2015:571\u2013578","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"3114_CR6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1200\/JCO.2014.57.1950","volume":"33","author":"J Haroche","year":"2015","unstructured":"Haroche J, Cohen-Aubart F, Emile JF et al (2015) Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAFV600E-mutated Erdheim-Chester disease. J Clin Oncol 33:411\u2013418","journal-title":"J Clin Oncol"},{"key":"3114_CR7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2014-12-569301","volume":"126","author":"CE Allen","year":"2015","unstructured":"Allen CE, Ladisch S, McClain KL (2015) How I treat Langerhans cell histiocytosis. Blood 126:26\u201335","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-3114-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3114-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3114-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T13:45:46Z","timestamp":1570023946000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-3114-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,23]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["3114"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3114-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,23]]}}}